Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim with Ipilimumab in Solid Tumors
NCT05284214Phase 2Withdrawn
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sargramostim in solid tumor (2 arms). Primary endpoint: The number of participants with severe, life-threatening or fatal adverse events up to 36 weeks. Planned start Jan 2024; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05284214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284214.